- Home
- GIGM vs BIVI Comparison
GIGM vs BIVI Comparison
Compare GIGM & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- BIVI
- Stock Information
- Founded
- GIGM 1998
- BIVI 2013
- Country
- GIGM Taiwan
- BIVI United States
- Employees
- GIGM N/A
- BIVI N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- BIVI Health Care
- Exchange
- GIGM Nasdaq
- BIVI Nasdaq
- Market Cap
- GIGM 17.9M
- BIVI 18.6M
- IPO Year
- GIGM 2000
- BIVI N/A
- Fundamental
- Price
- GIGM $1.39
- BIVI $0.93
- Analyst Decision
- GIGM
- BIVI Strong Buy
- Analyst Count
- GIGM 0
- BIVI 1
- Target Price
- GIGM N/A
- BIVI $30.00
- AVG Volume (30 Days)
- GIGM 29.6K
- BIVI 210.0K
- Earning Date
- GIGM 07-30-2025
- BIVI 05-12-2025
- Dividend Yield
- GIGM N/A
- BIVI N/A
- EPS Growth
- GIGM N/A
- BIVI N/A
- EPS
- GIGM N/A
- BIVI N/A
- Revenue
- GIGM $3,103,000.00
- BIVI N/A
- Revenue This Year
- GIGM N/A
- BIVI N/A
- Revenue Next Year
- GIGM N/A
- BIVI N/A
- P/E Ratio
- GIGM N/A
- BIVI N/A
- Revenue Growth
- GIGM N/A
- BIVI N/A
- 52 Week Low
- GIGM $1.26
- BIVI $0.62
- 52 Week High
- GIGM $1.80
- BIVI $7.50
- Technical
- Relative Strength Index (RSI)
- GIGM 43.40
- BIVI 36.15
- Support Level
- GIGM $1.41
- BIVI $1.00
- Resistance Level
- GIGM $1.45
- BIVI $1.07
- Average True Range (ATR)
- GIGM 0.05
- BIVI 0.07
- MACD
- GIGM -0.00
- BIVI -0.02
- Stochastic Oscillator
- GIGM 9.62
- BIVI 3.00
About GIGM GigaMedia Limited
GigaMedia Ltd is a publisher of online games. It has only one reportable segment, Digital Entertainment service. Digital Entertainment service business operates a portfolio of online games, mainly targeting online game players across Europe, and Asia, including Greater China and Southeast Asia. The company's portfolio of online games includes predominantly PC-based, non-cash gambling, or casino casual games, including MahJong and various card and table games. The company's product lines include MahJong, AkaSeka, Yume 100, Fun Vegas, and others. The company operates in Taiwan and Hong Kong.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.